The unprecedented trial of two former officials of the American Israel Public Affairs Committee, who are charged under the Espionage Act with unlawful receipt and disclosure of national defense information, is likely to be postponed from its scheduled start date on June 4.
The need to resolve disagreements between the parties over the handling of classified information involved in the case will “knock the trial date into a cocked hat,” said Judge T.S. Ellis, III at an April 19 hearing.
The Judge gave prosecutors until May 2 to decide whether they will propose a new set of “substitutions” for classified evidence, which would then need to be reviewed by the defense and the court under the provisions of the Classified Information Procedures Act.
Alternatively, prosecutors may decide to stand fast with their previous proposal to bar public access to the classified evidence, a position that the judge has already rejected, thereby setting the stage for an appeal.
Judge Ellis issued a detailed memorandum opinion (pdf) on April 19 to explain why he concluded that the prosecution proposal to exclude public access to classified evidence is not authorized by statute or precedent.
The memorandum opinion advised the government that any proposal to exclude public access to classified evidence would have to be thoroughly supported by “a highly detailed explanation of the ensuing harms to national security… [since] much of the classified information at issue [here] is not self-evidently damaging to national security.”
The transition to a clean energy future and diversified sources of energy requires a fundamental shift in how we produce and consume energy across all sectors of the U.S. economy.
A deeper understanding of methane could help scientists better address these impacts – including potentially through methane removal.
While it is reasonable for governments to keep the most sensitive aspects of nuclear policies secret, the rights of their citizens to have access to general knowledge about these issues is equally valid so they may know about the consequences to themselves and their country.
Advancing the U.S. leadership in emerging biotechnology is a strategic imperative, one that will shape regional development within the U.S., economic competitiveness abroad, and our national security for decades to come.